-$0.94 Earnings Per Share Expected for Revance Therapeutics, Inc. (RVNC) This Quarter
Analysts forecast that Revance Therapeutics, Inc. (NASDAQ:RVNC) will report ($0.94) earnings per share (EPS) for the current quarter, Zacks Investment Research reports. Two analysts have made estimates for Revance Therapeutics’ earnings. The lowest EPS estimate is ($1.01) and the highest is ($0.87). Revance Therapeutics posted earnings per share of ($0.64) in the same quarter last year, which indicates a negative year over year growth rate of 46.9%. The firm is expected to report its next quarterly earnings report after the market closes on Thursday, November 2nd.
According to Zacks, analysts expect that Revance Therapeutics will report full-year earnings of ($3.57) per share for the current year, with EPS estimates ranging from ($3.86) to ($3.00). For the next fiscal year, analysts anticipate that the business will report earnings of ($3.38) per share, with EPS estimates ranging from ($4.05) to ($2.85). Zacks’ earnings per share averages are an average based on a survey of research firms that follow Revance Therapeutics.
Revance Therapeutics (NASDAQ:RVNC) last issued its quarterly earnings data on Thursday, August 3rd. The biopharmaceutical company reported ($0.90) EPS for the quarter, topping the consensus estimate of ($0.93) by $0.03. Revance Therapeutics had a negative net margin of 32,936.67% and a negative return on equity of 55.21%. The firm had revenue of $0.08 million for the quarter, compared to analyst estimates of $0.05 million. During the same period in the prior year, the business posted ($0.88) EPS. The business’s revenue for the quarter was up .0% compared to the same quarter last year.
RVNC has been the topic of several research analyst reports. Zacks Investment Research raised shares of Revance Therapeutics from a “hold” rating to a “buy” rating and set a $26.00 target price on the stock in a research report on Tuesday, August 22nd. Piper Jaffray Companies set a $28.00 price target on shares of Revance Therapeutics and gave the company a “buy” rating in a research report on Wednesday, July 26th. BidaskClub raised shares of Revance Therapeutics from a “hold” rating to a “buy” rating in a research report on Thursday, July 6th. Finally, Cantor Fitzgerald reaffirmed a “buy” rating and set a $50.00 price target on shares of Revance Therapeutics in a research report on Wednesday, September 6th. Three equities research analysts have rated the stock with a hold rating and four have assigned a buy rating to the stock. The company has an average rating of “Buy” and an average target price of $35.20.
In other Revance Therapeutics news, CFO Lauren P. Silvernail sold 11,164 shares of Revance Therapeutics stock in a transaction that occurred on Thursday, October 12th. The shares were sold at an average price of $26.67, for a total transaction of $297,743.88. The sale was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Also, CEO L Daniel Browne sold 22,800 shares of Revance Therapeutics stock in a transaction that occurred on Wednesday, August 23rd. The shares were sold at an average price of $22.76, for a total transaction of $518,928.00. Following the transaction, the chief executive officer now directly owns 178,850 shares in the company, valued at $4,070,626. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 49,226 shares of company stock worth $1,196,318. 18.86% of the stock is currently owned by corporate insiders.
Hedge funds have recently made changes to their positions in the business. Legal & General Group Plc lifted its position in Revance Therapeutics by 8.1% during the second quarter. Legal & General Group Plc now owns 5,815 shares of the biopharmaceutical company’s stock valued at $152,000 after buying an additional 438 shares in the last quarter. Bank of America Corp DE lifted its position in Revance Therapeutics by 29.5% during the first quarter. Bank of America Corp DE now owns 7,247 shares of the biopharmaceutical company’s stock valued at $151,000 after buying an additional 1,651 shares in the last quarter. Trexquant Investment LP acquired a new position in Revance Therapeutics during the second quarter valued at approximately $231,000. Voya Investment Management LLC acquired a new position in Revance Therapeutics during the second quarter valued at approximately $274,000. Finally, American International Group Inc. lifted its position in Revance Therapeutics by 7.1% during the first quarter. American International Group Inc. now owns 12,590 shares of the biopharmaceutical company’s stock valued at $262,000 after buying an additional 834 shares in the last quarter. 89.32% of the stock is currently owned by hedge funds and other institutional investors.
Shares of Revance Therapeutics (NASDAQ RVNC) traded down 0.59% during trading on Wednesday, hitting $25.35. 81,424 shares of the stock traded hands. The company’s 50 day moving average is $25.99 and its 200 day moving average is $23.74. Revance Therapeutics has a 52-week low of $12.35 and a 52-week high of $28.75. The firm’s market cap is $781.26 million.
Revance Therapeutics Company Profile
Revance Therapeutics, Inc is a clinical-stage biotechnology company. The Company is focused on the development, manufacturing and commercialization of botulinum toxin products for multiple aesthetic and therapeutic indications. Its peptide technology enables delivery of botulinum toxin type A through two investigational drug product candidates, DaxibotulinumtoxinA for Injection (RT002), or RT002 injectable, and DaxibotulinumtoxinA Topical Gel (RT001), or RT001 topical.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Revance Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Revance Therapeutics Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.